Novartis Shares Bolstered by Kidney Disease Therapy Milestone
Novartis’s Fabhalta shows 49.3% slower kidney decline in IgA nephropathy trial, securing FDA Priority Review and bolstering its…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…